Form 4: Medpace Director Carley Receives 143 Restricted Stock Units

Medpace Holdings, Inc. Director Brian T. Carley was granted 143 restricted stock units, vesting over four installments through December 2026.

Summary

• Brian T. Carley, a Director of Medpace Holdings, Inc. (MEDP), reported changes in beneficial ownership.
• Carley acquired 143 Restricted Stock Units (RSUs) on November 28, 2025.
• Each RSU represents a contingent right to receive one share of MEDP common stock.
• The RSUs will vest in four approximately equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• The price of the derivative security (RSU) was $592.46.
• Following this transaction, Carley directly beneficially owns 26,219 shares of common stock and 143 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is generally a positive sign of alignment between management and shareholder interests, though it doesn't indicate extraordinary news.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with the company's long-term performance and shareholder value creation.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends through December 2026, indicating a future alignment of the director's incentives with the company's long-term performance.

Industry Context

Equity grants like Restricted Stock Units are a common form of executive and director compensation in the pharmaceutical and contract research organization (CRO) industries, aiming to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a standard practice in corporate governance across various industries, including the CRO sector where Medpace operates.
• Companies like IQVIA Holdings Inc. (IQV) and Laboratory Corporation of America Holdings (LH) also utilize equity-based compensation to retain and motivate key personnel.
• The specific number of units and vesting schedule would typically be benchmarked against peer companies of similar size and market capitalization to ensure competitive compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's long-term interests with shareholder value creation, potentially fostering more strategic decision-making.

Next Steps

• Vesting of Restricted Stock Units in four installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation package. While it signifies continued alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on existing fundamental analysis.

Keywords

Medpace Holdings, MEDP, Brian T. Carley, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant